Hydrochlorothiazide/Irbesartan

氢氯噻嗪/厄贝沙坦

Report date: 2023/04/21 09:51:06

Base Information

Drug NameHydrochlorothiazide/Irbesartan
Drug Alias Name氢氯噻嗪厄贝沙坦Hydrochlorothiazide and IrbesartanIrbesartan and Hydrochlorothiazide厄贝沙坦/氢氯噻嗪Irbesartan/Hydrochlorothiazide +[12] 
ClassificationSmall molecules
Mechanisms of ActionThiazide-sensitive sodium-chloride cotransporter inhibitorsAngiotensin II Receptor Type 1 antagonists
TargetsThiazide-sensitive sodium-chloride cotransporterAngiotensin II Receptor Type 1
Therapy Area/IndicationsEssential HypertensionHypertension
Global Approved IndicationsHypertension
Approved Indications in ChinaHypertension
Original Approved Country/TerritoryUnited States
Original Approved Date1997/09/30
Country/TerritoryUnited StatesEUMainland China
CombinationsYes HydrochlorothiazideIrbesartan
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesSanofi-Aventis U.S. LlcSanofi PharmaSanofi Winthrop Industrie SA
Inactive CompaniesBristol-Myers Squibb Pharma Eeig
Active IndicationsHypertension
Inactive IndicationsEssential Hypertension

Other Information

ATC CodeC09DA04
Related LinksKEGG